Pinned Tweet
We are excited to launch OCCAM Immune, an Academic Research Organization providing streamlined #ImmuneMonitoring services to the pharma and biotech industry for clinical studies.
Check out the immune monitoring as a service options we provide here >>> occam-immune.com/
OCCAM Immune retweeted
Now add success for an acute myelogenous leukemia (AML) vaccine, a 41% reduction of death, extending survival for nearly a year, a Phase 2 randomized trial
fiercebiotech.com/biotech/se…
The mRNA vaccine success vs melanoma in a Phase definitive 3 randomized trial today is on top of signs of success for personalized mRNA neoantigen vaccines vs pancreatic cancer, triple negative breast cancer, and non-small cell lung cancer wsj.com/health/pharma/modern…
🔬 A hands-on start to FAAM–EUROBAT–ISMA 2026!
This afternoon in Utrecht, participants put Basophil Activation Testing (BAT) into practice during a pre-meeting course. Working in small groups, they performed the tests using two widely used commercial kits and an in-house method, gaining first-hand experience with each approach.
Short talks from experts complemented the practical sessions, giving participants the chance to compare techniques, ask questions and discuss how BAT can inform clinical practice.
The course marked 10 years since the last hands-on BAT course at FAAM–EUROBAT, held in Rome in 2016. It was also a fitting location, as the foundations of BAT were first published in the Netherlands 35 years ago.
Thank you to the course faculty, organisers and everyone who took part. See you tomorrow for the opening of FAAM–EUROBAT–ISMA 2026!
#FAAMEUROBATISMA2026 #EAACI #BasophilActivationTesting #AllergyDiagnostics #Utrecht
OCCAM Immune retweeted
Whether the immune system recognizes and eliminates cancer was unclear until the 1950s, when immunization of mice with tumor cells generated protective immunity against new tumors.
Lymph node cells, but not serum, could transfer this protection across animals, which suggested that antitumor immunity is cellular rather than mediated by secreted molecules. Later, cytotoxic CD8+ T cells, which kill damaged or diseased cells, emerged as central mediators of anticancer immunity and immune surveillance.
Much of modern cancer immunology has therefore focused on understanding how these cells are activated, differentiate, are sustained, and become dysfunctional within tumors that escape surveillance. Yet CD8+ T cells do not act alone: Their differentiation and function are shaped by interactions with other immune cells.
In a new Science study, researchers report how these immune microenvironments affect the responses of colorectal tumors to immunotherapy.
Learn more in this #SciencePerspective: scim.ag/3VpChiu
At #FAAMEUROBATISMA2026 in Utrecht this week? Meet our CEO and allergy immunologist Erik Wambre (@WambreErik ) to discuss how our immune monitoring, from basophil activation testing to allergen-specific T cell profiling, can support your allergy programs. DM us!
Learn more about our allergy immune monitoring assays:
ASTERA antigen-specific T cell assay: occam-immune.com/services-so…
Basophil Activation Test: occam-immune.com/services-so…
1
13
OCCAM Immune retweeted
Thomas Marron, MD, PhD, presents tomorrow: "Inflammaging & Cancer"
profiles.mountsinai.org/thom…
@IcahnMountSinai
Our CMO Dr. Thomas Marron (@DrTomMarron) has been a force for OCCAM Immune at #SITC26! Here he is at Booth #1031 with our CEO Erik Wambre (@WambreErik) and CSO Seunghee Kim-Schulze, talking spatial profiling of the tumor microenvironment. #ImmunoOncology
Tomorrow at #SITC26: our CSO Seunghee Kim-Schulze presents Poster #148 in the Poster Hall. Catch her at lunch (12–1:30 pm MT) or the poster reception (6:40–8:10 pm MT).
Until then, find us and CEO @WambreErik at Booth #1031! #ImmunoOncology
35
Today at #SITC26: our CMO Dr. @DrTomMarron co-leads the New Agents in Development and Emerging Tech program and speaks at 3:40 pm MT on how AROs use biospecimens to inform drug development.
Want to keep the conversation going? Visit Booth #1031 on November 6–7
1
29
OCCAM Immune is at #SITC26 in Phoenix next week!
Visit us at Booth #1031, Nov 6–7.
Come talk with our CEO Erik Wambre (@WambreErik) and CSO Seunghee Kim-Schulze about immune monitoring for your translational research and clinical trials.
#ImmunoOncology
OCCAM Immune retweeted
16-channel imaging of Ovarian Serous Cystadenocarcinoma, acquired on the Orion Spatial Biology platform. 🌟
Image is courtesy of Zhihong Chen and custody of Human Immune Monitoring Center, @Occamimmune, @IcahnMountSinai.
#SpatialBiology #SpatialProteomics #OvarianCancer
Happy Holidays from the OCCAM Immune Team! 🎄
Thank you to all our partners and supporters for an amazing year. We’re excited for what’s ahead in 2025 and look forward to continuing this journey together.
Wishing you a joyful holiday season!
#HappyHolidays #Immunology
OCCAM Immune retweeted
Excited to see that I rank among the highest cited people in the field of immunology and medicine. Proud of our work! #researcher #research #immunology #medicine #mountsinai #dermatology #skin #disease #translational #eczema #allergy #alopecia #treatment #inflammation #aging
Excited to announce that our CEO Erik Wambre, will be presenting "Immunophenotypes of Food Allergy & Responses to Immunotherapy Across the Life Course" Friday Nov 22 at the @EAACI_HQ FAAM-EUROBAT conference in Athens, Greece!
Reach out if you'd like to meet—we’d love to connect!
1
89
DM if you'd like to meet the @OCCAMimmune team at the 'Next Generation Immunotherapy Discoveries' symposium Oct 3.
We'd love to introduce our custom immune profiling capabilities to investigators & industry representatives planning clinical trials of cutting-edge immunotherapy.
Join us ONLINE Oct 3 for a joint symposium hosted by @InnatePharma & @IcahnMountSinai to find out what upcoming immunotherapy strategies are envisioned by @MiriamMerad @EricVivier @EJohnWherry & more.
Don’t miss out—register now for FREE: innate-symposium.com/
👇 Program 👇
164
JOIN US in-person at the 'Next Generation Immunotherapy Discoveries' Symposium, Oct 3rd in NYC, a great opportunity to meet CEO @ErikWambre & discuss cutting edge immune monitoring for clinical studies of new immunotherapies at the lunch or cocktail reception:
Discover how the @Occamimmune mass cytometry panel helped Samir Parekh and @ovanoekelen uncover how Iberdomide activates immune cells to fight cancer in the bone marrow of patients with relapsed/refractory #MultipleMyeloma. Study in @CellRepMed 👇
loom.ly/UM5gtxk
Iberdomide is a CELMoD: a new class of immunomodulatory drugs for treating myeloma. We employed standardized mass cytometry to show that Iberdomide enhances effector T and NK cells, offering new mechanistic insights into how Iberdomide boosts innate and adaptive tumor immunity.
1
1
115
Explore our full range of cutting-edge technologies for immunophenotyping patient responses to new immunotherapies to reveal how they work here >>> occam-immune.com.
2
80






















